BPC-157 + TB-500 combined research vial (10mg/10mg)

BPC-157 and TB-500 together: research on each component

This vial pairs two peptides that often come up together, and readers frequently ask about BPC-157 vs TB-500. Before we get comfortable, one important point: the studies below looked at each peptide separately, never as a pair.

Please note: Snowman Research does not offer dosing information or usage guidance of any kind. Everything we list, this item included, is sold strictly for research purposes and nothing else.

Published findings

BPC-157's published record is dominated by animal research. A 2025 systematic review counted 35 preclinical studies and a single retrospective clinical report among 36 included papers, and it found no clinical safety data ^[1]. Older reviews describe rodent injury models across the digestive tract and the musculoskeletal system ^[2]. Thymosin beta-4, the parent of TB-500, has been studied in skin, eye, heart and brain models ^[3], yet the FDA notes it has found no human exposure data for the TB-500 fragment itself ^[4]. No cited paper has examined whether the two peptides interact, stay stable together, or produce any combined effect.

Mechanism at a glance

BPC-157: a 15-residue synthetic peptide; researchers propose angiogenic and growth-factor-related activity, without a single identified receptor ^[2]. TB-500: a synthetic thymosin beta-4 fragment, which the FDA lists as LKKTETQ ^[4]. The full-length parent peptide binds actin and supports cell migration during repair ^[3].

Regulatory & WADA notes

On the FDA's page about bulk substances that may present significant compounding risks, both BPC-157 and the thymosin beta-4 fragment (TB-500) are listed as previously in category 2 with nominations withdrawn ^[4]. Under WADA's 2026 Prohibited List, BPC-157 is a named S0 non-approved substance and TB-500 is a named S2.3 growth-factor modulator; both are prohibited at all times ^[5].

Thanks for reading. Stay warm, and keep your bench notes tidy.

Further reading

1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID 40756949. https://pubmed.ncbi.nlm.nih.gov/40756949/
2. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID 29998800. https://pubmed.ncbi.nlm.nih.gov/29998800/
3. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID 22074294. https://pubmed.ncbi.nlm.nih.gov/22074294/
4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, human drug compounding web page (accessed Oct 4, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
5. World Anti-Doping Code International Standard: Prohibited List 2026 (in effect 1 January 2026). World Anti-Doping Agency, 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

For laboratory research use only. This product is not intended for human or veterinary use and is not an FDA-approved drug; nothing on this page is medical advice. You must be 21 or older to purchase.